Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio.

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro soared in the first quarter.

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...

Modern Family’ alum Eric Stonestreet opened up to PEOPLE about living with type 2 diabetes and being unable to get a grasp on ...

To help spread the message that managing Type 2 diabetes “doesn’t have to be a solo act,” Eli Lilly, fittingly, is assembling ...

Key takeaways Eli Lilly has filed lawsuits against four telehealth companies—Mochi Health, Fella Health, Willow Health, and ...

Stonestreet was diagnosed with type 2 diabetes in 2009, but kept it a secret. He told Business Insider why he's speaking out ...

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%).

Lilly's weekly prescription data for Zepbound is up 354% year-over-year, while Novo's Wegovy is up just 61%. That's based on ...

Eli Lilly LLY-0.26%decrease; red down pointing triangle revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio. The drug maker logged ...